Medicus extends Phase II study in nodular basal cell carcinoma
Medicus Pharma has announced plans to extend its SKNJCT-003 Phase II clinical study for the treatment of nodular basal cell carcinoma (BCC). The Institutional Review Board (IRB) has approved the increase in the number of patients from 60 to 90. The trial will expand into… Read More